Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 7/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13465435 | 0.92 | PARP1 (0.49) | METPARP1JAK3JAK1HTR1A | |
| SCHEMBL13449289 | 0.91 | PARP1 (0.40) | METPARP1JAK3HTR1AHTR1D | |
| SCHEMBL13465487 | 0.91 | PARP1 (0.41) | METPARP1JAK3JAK1 | |
| SCHEMBL13465736 | 0.91 | MGLL (0.45) | PARP1 | |
| SCHEMBL255442 | 0.91 | RORC (0.40) | PARP1SIRT2 | |
| SCHEMBL12517697 | 0.90 | PARP1 (0.38) | METPARP1JAK3JAK1 | |
| SCHEMBL165695 | 0.90 | PARP1 (0.40) | METPARP1JAK3JAK1SIRT2 | |
| SCHEMBL13465493 | 0.90 | PARP1 (0.40) | METPARP1JAK3JAK1 | |
| SCHEMBL2221301 | 0.90 | PARP1 (0.42) | METPARP1JAK3JAK1LRRK2 | |
| SCHEMBL13449287 | 0.90 | HPGD (0.42) | METPARP1HTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | MET 2/4885PARP1 2307/4885JAK3 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.